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Members of the Bactevoider fragilis group of anaerobes 
are the most frequently encountered anaerobic patho- 
gens in clinical infections. The traditional antimicrobial 
therapy has usually included metronidazole, to which, 
in addition, many of the other groups of anaerobes are 
susceptible [l]. In the past, Bacteroides spp. have shown 
remarkable stability to the in vitro activity of metro- 
nidazole. Sporadic single case reports of metronidazole- 
resistant Bacteroides spp. have been appearing in the 
literature since 1978 [2-81. In most of these reports, 
resistant isolates were detected initially by the absence 
of a zone of inhibition around a 5-pg metronidazole 
disk on a primary plate. Hence, it is conceivably correct 
to assume that there could have been some degree of 
under-reporting of metronidazole resistance in the 
usually busy clinical routine laboratories, many of 
which use a zone of inhibition around the 5-pg 
metronidazole disk placed on a primary plate culture as 
an indication of the presence of anaerobes in clinical 
specimens. However, until now this resistance pheno- 
menon had posed little, if any, clinical problem in 
Kuwait [9]. Unfortunately, however, only a few labora- 
tories actually report the presence of anaerobes in 
clinical specimens, and, moreover, Kuwait being an 
affluent country, there are many other antibiotic thera- 
peutic options available to choose from. As anticipated, 
high-level metronidazole-resistant Bacteroides strains 
with increased MICs for some other useful anti- 
anaerobic agents are emerging. In this communication 
we report five highly metronidazole-resistant Bacteroides 
spp. isolated fi-om three patients. 
CASE REPORTS 
Case 1 
A 75-year-old Indian woman was admitted on 10 June 
1997 because of diffuse colicky abdominal pain, vomit- 
ing and constipation of 2 days’ duration. On examina- 
tion, she was afebrile, and obviously in pain, with a 
distended abdomen. Erect plain X-ray of the abdomen 
showed multiple fluid levels in the small intestine and 
a distended large intestine. Hematologic investigations 
revealed leukocytosis of 21.0X 109/L, mainly poly- 
morphonuclear leukocytes (PMNs), and a hemoglobin 
level of 10.4 g/&. Because of a stenosing mass seen in 
the rectosigmoid area by sigmoidoscopy on the third 
day, laparotomy and Hartmann’s procedure were 
performed. She was started on intravenous ceftazidime, 
2 g twice daily (bd) for 10 days, and intravenous 
metronidazole, 500 mg three times daily (tds) for 11 
days. The immediate postoperative period was 
uneventful. Meanwhile, histologic results from the 
sigmoid colon confirmed the diagnosis of chronic 
diverticular disease. Her wound became infected 14 
days later, but responded well to antibiotic manage- 
ment, and she was discharged home 11 days later. 
On a second admission 15 days later, a paracolic 
abscess seen on CT scan was drained and the pus 
specimen sent to the microbiology laboratory for 
investigations. Imipenem, 500 mg tds, was com- 
menced. Her wound healed nicely and she was 
subsequently discharged. Follow-up at the surgical 
outpatient department was uneventful. 
Case 2 
A 40-year-old Bangladeshi man was admitted on 24 
November 1997 to the main surgical ward because of 
diffuse abdominal pain and vomiting of 3 days’ 
duration. On examination, he looked ill, febrile 
(38.3OC), and tachycardic. The abdomen was slightly 
distended with marked rebound tenderness and 
guarding in the right iliac fossa. He had a white blood 
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cell W C )  count of 10.2x109/L (mainly poly- 
morphs), with a hemoglobin level of 15.0g/dL. At 
laparotomy, a gangrenous appendix, with perforation at 
the base, was found. The appendix was completely 
separated Gom the cecum. Appendectomy was com- 
pleted and the cecal perforation closed with part of the 
mesoappendix. Peritoneal swab, pus and appendeceal 
tissue were sent to the microbiology laboratory for 
culture and sensitivity testing. The patient was started 
on intravenous metronidazole 500 mg and cefuroxime 
750 mg perioperatively, and this was continued tds for 
5 days. Despite the broad-spectrum antibiotic therapy 
he developed wound infection 5 days postoperatively; 
wound swab was sent to the laboratory. His infection 
was cleared with intravenous amoxycillin/clavulanic 
acid, 600 mg tds for 6 days. He made remarkable 
progress and was discharged home on the 23rd day after 
hospital admission. 
Case 3 
A 37-year-old Syrian, with a past history of renal 
transplant surgery, was admitted to the surgical ward on 
11 November 1997 because of jaundice, abdominal 
pain and dark discoloration of the urine of 2 days' 
duration. He was on triple immunosuppressive therapy 
(prednisolone, cyclosporin and azathioprine) and other 
medications, including nifedipine, for high blood 
pressure. 
On examination, he was afebrile but tender over 
the right upper quadrant of the abdomen. Other 
systems were normal. Ultrasound of the abdomen 
showed multiple gallbladder stones and a stone in the 
common bile duct confirmed by a cholangiogram. He 
had a white blood cell (WBC) count of 7.8 X 109/L, 
with deranged liver function tests. During the first 10 
days of admission, he had a sphincterectomy, ERCP 
and laparoscopic cholecystectomy. Despite receiving an 
adequate dose of intravenous ceftriaxone, he developed 
a series of complications, including fever of 39OC, 
paralytic ileus, generalized abdominal distension, 
pancreatitis, epididymo-orchitis, and, later, pleural 
effusion, diffuse inflammation of the pancreas extend- 
ing to involve the posterior abdominal wall and 
hydrocele. These were accompanied by marked leuko- 
cytosis of 24.9X10y/L. The patient was then moved 
into the intensive care unit on 20 November 1997. 
Amikacin, 500 mg given once daily (od), and intra- 
venous metronidazole, 500 mg tds, were commenced 
in addition to the ceftriaxone. This triple antibiotic 
regimen was stopped 2 days later, and meropenem, 1 g 
tds, was substituted. He also received liposomal 
amphotericin B when his high fever persisted and 
positive candida antigenemia (titer of 1:4) was 
demonstrated in his serum plus heavy growth of 
Candida albicans in the endotracheal tube secretion. 
Following a CT scan of the abdomen on 1 December, 
which showed a huge collection of pus, a laparotomy 
was performed. At laparotomy, necrotizing pancreatitis 
with multiple abscesses was found. Necrotic tissue and 
pus specimens were sent to the microbiology laboratory 
for investigation. 
The patient's post-laparotomy period was very 
eventful. On 22 December, all the antimicrobial agents 
were stopped. Between this time and 5 January 1998, 
three interventional laparotomies were performed to 
debride and resect extensive necrotic intra-abdominal 
tissues and gangrenous transverse colon. The antibiotic 
cover included intravenous meropenem, 1 g tds, and 
intravenous amikacin, 500 mg bd. On 11 January, 
about 1 L of pus was drained from the groin and scrotal 
abscess. 
All the bacterial isolates at this stage were resistant 
to almost all available antibiotics. The patient remained 
on meropenem, cefepime and amikacin as the only 
feasible combination to deal with all the multiresistant 
isolates. However, his condition continued to deteriorate 
and he consequently died on 28 January. 
MICROBIOLOGICAL INVESTIGATIONS 
In the laboratory, all pus specimens and necrotic tissues 
were cultured on a set of selective (blood agar 
supplemented with gentamicin, 75 mg/L) and non- 
selective media (MacConkey agar and plain blood 
agar). The MacConkey agar and plain blood agar were 
incubated in air at 37OC for 24 h, while the blood agar 
supplemented with gentamicin, with a metronidazole 
5 p,g disk placed on the surface, and another plain 
blood agar were incubated in the anaerobic jar (Oxoid 
Ltd, Basingstoke, UK) at 37OC for 48 h and reincubated 
for another 5 days if there was no growth. Anaerobiosis 
in the jar was achieved by the use of the Gas Generating 
Kit System (Oxoid Ltd) with appropriate controls. 
After incubation, representative colonies of facultative/ 
aerobic bacteria and the different representative 
colonies of anaerobes, growing on the blood agar sup- 
plemented with gentamicin, were identified by the 
Vitek Aerobic and Anaerobic Card System (bioMerieux 
Vitek Inc., Hazelwood, MO, USA), respectively. The 
susceptibility of the anaerobic isolates was determined 
by estimating the MICs of metronidazole, amoxycillin/ 
clavulanic acid, clindamycin, cefoxitin, meropenem, 
imipenem, piperacillin, and piperacillin/tazobactam, 
using the Etest (AB Strips Biodisk, Solna, Sweden) and 
the agar dilution method (for metronidazole only) in 
accordance with the recommendation of the National 
Committee for Clinical Laboratory Standards 
(NCCLS). [lo] Both tests were carried out under strict 
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anaerobiosis in the anaerobic chamber (Ruskinn Tech. 
Ltd, Guiseley, Leeds, UK) in our Anaerobe Research 
Laboratory. Testing for p-lactamase production by the 
strains was performed using nitrocefin disks (cefinase 
disks) (BBL, Microbiology Systems, USA). 
RESULTS 
The pus specimens of the first case yielded an anaerobic 
Gram-negative bacterium which grew only on the 
blood agar supplemented with gentamicin after 48 h. 
Although the colonial morphology and Gram-stained 
smear suggested Bacteroides spp., there was no zone of 
inhibition around the 5 p,g metronidazole disk. The 
organism (designated MHKI) was identified as 
B. fragilis and was highly resistant to metronidazole, 
with an MIC of >32mg/L by the Etest and of 
128 mg/L by the agar dilution method. The MICs for 
all the isolates as determined by the Etest are shown in 
Table 1. 
For the second case, the initial set of peritoneal 
swab, pus and tissue specimens yielded mixed growth 
of sensitive strains of Escherichia coli, Pseudomonas 
aeruginosa and B. fragilis. However, the wound swab 
yielded B.fragilis (MHK2) and B. ovatus (MHK3) that 
were both resistant to metronidazole (MIC >32 mg/L 
by Etest and 128 mg/L by the agar dilution method). 
Specimens taken at laparotomies from the third 
case, between 22 December 1997 and 5 January 1998, 
grew multiresistant Pseudomonas aeruginosa and B. 
distasonis. The B. distasonis strain (MHK4) was resistant 
to metronidazole (MIC >32 mg/L and >128 mg/L). 
Culture of the scrota1 material yielded mixed growth of 
multiresistant Pseudomonas aeruginosa, B. distasonis 
(MHKS), with an identical resistance profile to that of 
MHK4 (see Table I), and metronidazole-sensitive 
strains of Prevotella melaninogenica and Peptostreptococcus 
magnus. All the metronidazole-resistant strains were 
identified and their susceptibilities confirmed in the 
laboratory of J. S. Brazier at the PHLS Anaerobe 
Reference Unit, University Hospital of Wales, Cardiff, 
UK. 
These strains were p-lactamase positive and highly 
resistant to piperacillin and cefoxitin, with MICs 
ranging from 32 to 128 mg/L. Three of the five strains 
were susceptible to piperacillin/tazobactam, with an 
MIC of 64 mg/L, while the remainder were resistant 
(MIC >128 mg/L). The strain isolated from the last 
patient was highly resistant to imipenem and mero- 
penem, with MICs >32 mg/L, and another two strains 
had relatively high MICs of 6-8 mg/L (upper limit of 
their breakpoints). 
DISCUSSION 
Metronidazole resistance of Gram-negative anaerobes 
and clostridia has remained rare despite several years of 
usage [ll]. The first B. fragilis strain resistant to 
metronidazole was reported in 1978 by Ingham et a1 [2] 
in a patient with Crohn's disease during long-term 
metronidazole therapy. The majority of the other 
reports have also been associated with previous 
exposure of varying duration [4-81, although a 
metronidazole-resistant B. distasonis strain has also been 
reported in a 9-year-old boy with peritonitis who had 
not received previous metronidazole therapy [3]. 
All our patients were on metronidazole therapy for 
25, 5 and 5 days respectively prior to isolation of the 
metronidazole-resistant strains. The first patient 
received metronidazole for a total of 25 days during two 
admissions, although patients 2 and 3 received the drug 
only for 5 days. It was, therefore, not totally surprising, 
judging from the experience of others, that 
metronidazole-resistant strains were isolated from 
them. However, the second and third cases were not 
exactly the same. We do not know whether or not 
these two patients had received metronidazole therapy 
before admission but no such history was volunteered. 
Patient 2 received a single dose of metronidazole 
500 mg during the induction of anesthesia and a 5-day 
Table 1 The susceptibility pattern of the five metronidazole-resistant Bacteroides fragilis group 
Minimum inhibitory concentrations (mg/L) 
Bacterial Amoxycillin/ Piperacillin/ 
strains clavulanic acid Metronidazole Meropenem Imipenem Piperacillin tazobactam Clindamycin Cefoxitin Erythromycin 
MHKl 3 > 32 8 6 > 128 128 0.016 >128 > 128 
MHK2 2 > 32 1 1 2128 64 0.016 128 > 128 
MHK3 12 > 32 8 8 1128 64 2 32 >128 
MHK4 16 >32 > 32 1 3 2  > 128 > 128 >128 >128 >128 
MHK5 16 >32 > 32 > 32 > 128 > 128 >128 >128 >128 
Bacterial strain MHKl was the B.  frugilis isolated from patient 1; MHK2 and MHK3 were B. fragilis and B. ovutus respectively, isolated b m  
patient 2; MHK4 and MHK5 were identical strains of B. distasonix from patient 3. 
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course thereafter. It is interesting to note that at the end 
of only 5 days of therapy, two Bacteroides spp. highly 
resistant to metronidazole (MIC > 128 mg/L) were 
isolated from his wound infection. The third patient 
was even more interesting in that, out of the total of 
78 days that he spent in the hospital, he only received 
metronidazole, given twice for a total of 5 days 
(November for 3 days and early December for 2 days); 
two identical strains of metronidazole-resistant B. 
distasonis were isolated 38 and 43 days later from two 
different sites. Previous evidence seems to suggest that 
short-term metronidazole chemotherapy does not give 
rise to significant acquisition of resistance, while long- 
term therapy may do so [2,4-81. However, four strains 
isolated from two of three of our patients appeared to 
have developed resistance after relatively short-term 
therapy. Besides, it is recognized that metronidazole- 
resistant Bacteroides spp. could be isolated from patients 
who had never been treated with metronidazole [3]. 
Patient 2 was a case of metronidazole treatment failure. 
Changing the therapy to amoxycillin/clavulanic acid 
cleared the wound infection within a few days. 
Therefore, clinical failure, thought to be non-existent 
a decade ago [12], appears to be emerging. 
Transferable resistance to metronidazole has been 
described in various strains of Bacteroides spp. Several 
mechanisms seem to be involved [13,14]. The existence 
of transferable mechanisms of resistance, already des- 
cribed in some strains, supports the possibility of intra- 
and interspecies spread of resistance occurring. 
These cases demonstrate emerging multiresistant 
strains of Bacteroides spp. in clinical infections with high- 
level metronidazole resistance, and evidence of clinical 
failure in at least one of them. Some countries, like 
Spain, already have a high incidence of metronidazole- 
resistant Bactevoides spp. [15]. It is also obvious that 
caution is needed when using 5 pg metronidazole disks 
on primary plates to indicate non-sporulating Gram- 
negative anaerobes. The results of inhibition around 
metronidazole disks may therefore be misleading in 
determining the true incidence of metronidazole- 
resistant anaerobes in hospitals. Diagnostic laboratories 
must also take note of the existence of artifactual 
resistance to metronidazole of the members of the B. 
fiagilis group-a false resistance associated with sus- 
ceptibility testing under suboptimal anaerobiosis [16]. 
Monitoring the susceptibility of strains of anaerobes 
isolated from clinical infections, preferably by MIC 
determination, under well-controlled anaerobic condi- 
tions (Eh<430 mV), is necessary as one ofthe measures 
to monitor the situation. Perception of local suscepti- 
bility patterns is a major factor in the selection of initial 
empirical antimicrobial therapy in hospitals. 
References 
1. Finegold SM, National Committee for Clinical Laboratory 
Standards Working Group on Anaerobic Susceptibility Testing. 
Susceptibility testing of anaerobic bacteria. J Clin Microbiol 
2. Ingham H R ,  Eaton S, Venables CW, Adams PC. Bacteroides 
jag i l i s  resistant to metronidazole after long term therapy. Lancet 
1978; 1: 214. 
3. Rotimi VO, Duerden BI, Ede V, Mackinnon AE. Metronidazole 
resistant Bacteroides from untreated patient. Lancet 1979; i: 833. 
4. Sprott MS, Ingham HR,  Hickman JE, Sisson PR.  Metronidazole 
resistant anaerobes. Lancet 1983; 1: 1220. 
5. McWalter PW, Baird DR. Metronidazole resistant anaerobes. 
Lancet 1983; i: 1220. 
6. Hickey MM, Davies UM, Dave J, Vogler M, Wall R. 
Metronidazole resistant Bacteroidesjqi l is  infection of a prosthetic 
hip joint. J Infect 1990; 20: 129-33. 
7. Eme Me A, Acar JF, Goldstein FW. Bacteroidesfragilis resistant to 
metronidazole. J Antimicrob Chemother 1983; 12: 523-4. 
8. ODonoghue MAT, Potter J, Allen A. Metronidazole-resistant 
Bacteroidesfragilis wound infection. J Infect 1992; 25: 21 1-14. 
9. Elhag KM, Mustafa AK, Pazhoor AA. The changing pattern of 
antibiotic susceptibilities of Bacteroides j q i l i s  in Kuwait. J 
Antitnicrob Chemother 1989; 24: 699-707. 
0. National Comtmttee for Clinical Laboratory Standards. Method 
for antimicrobial susceptibility testing of anaerobic bacteria. 
Approved Standard M11-A3. Villanova: NCCLS, 1993. 
1. Garcia-Rodriguez JA, Garcia-Sanchez JE, Munoz-Sellido JL. 
Antimicrobial resistance in anaerobic bacteria: current situation. 
Anaerobe 1995; 1: 69-80. 
2. Dublanchet A, Caillon J, Emond JP, Chandon H, Drugeon HB. 
Isolation of Bacteroides strains with reduced sensitivity to 5- 
nitroimidazoles. Eur J Clin Microbiol 1986; 5: 346-7. 
13. B r e d  J. Patey 0, Dublanchet A, Burnat C. Plasmid and non- 
plasmid mediated reduced sensitivity to metronidazole in the 
Bacteroidesfragilis group. Scand J Infect Dis 1990; 22: 247-8. 
14. Reysset G, Haggoud A, Sebald M. Genetics of resistance of 
Batteroides jag i l i s  species to 5-nitroimidazole. Clin Infect Dis 
15. Borobio MV, Pascual A, Perea EJ. Increasing resistance of 
BaLteroides jag i l i s  group strains to metronidazole in Spain 
between 1977 and 1982. Eur J Clin Microbiol 1984; 3: 153-5. 
16. Brazier JS, Hall V, Duerden BI. Artefactual resistance to 
metronidazole in anaerobes of the Bacteroides jag i l i s  group. J 
Antimicrob Chemother 1992; 30: 533-4. 
1988; 26: 1253-6. 
1993; lh(supp1): 401-3. 
